Bicycle Therapeutics Reports Q3 Results and Revenue Recognition from Bayer Agreement Termination

Filing content

The company reported an increase in Q3 revenue due to the recognition of remaining transaction price following the termination of its collaboration with Bayer, while continuing to record operating losses.